Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$99.39
-$0.81(-0.83%)
At close: 4:00 PM EDT
$99.39
-$0.81(-0.83%)
Day’s Range― - ―
52-Week Range$61.96 - $150.44
Previous Close$98
Volume370.05K
Average Volume (3M)609.93K
Market Cap
$4.62B
Enterprise Value$6.13B
Total Cash (Recent Filing)$548.63M
Total Debt (Recent Filing)$143.92M
Price to Earnings (P/E)148.9
Beta0.17
Next Earnings
Nov 04, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.69
Shares Outstanding42,644,386
10 Day Avg. Volume550,265
30 Day Avg. Volume609,926
Financial Highlights & Ratios
PEG Ratio-12.02
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue15.42
Enterprise Value/Gross Profit21.64
Enterprise Value/Ebitda121.98
Forecast
1Y Price Target
$128.83Price Target Upside29.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.79
Revenue Forecast (FY)$454.84M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue And Test GrowthStrong revenue and test-volume growth indicate expanding adoption of the company’s diagnostic offerings and increasing commercial reach. Management’s reiterated 2026 outlook supports the view that growth is expected to persist beyond a single quarter, creating a stronger base for operating scale.
High-Margin Technology And Product DifferentiationHigh gross margins combined with reported precision and low QC failure rates suggest meaningful product and workflow advantages. These characteristics can support customer value, operational efficiency, and sustained profitability as the company expands prenatal and oncology testing.
Improving Balance Sheet And LiquidityThe sharp reduction in leverage materially improves financial flexibility, while the large cash balance and positive quarterly free cash flow provide resources for commercial expansion, research, and laboratory capacity. This lowers balance-sheet risk during the company’s investment phase.
Bears Say
Thin Bottom-Line ProfitabilityAlthough the company has reached profitability, the current earnings cushion remains narrow. Modest cost increases, product-mix changes, or execution setbacks could therefore reduce reported earnings materially, making sustained margin discipline important as the business continues investing.
Reimbursement And Claims Timing RiskDelayed claims processing can defer cash collection and temporarily weaken realized pricing, creating volatility even when underlying testing demand remains healthy. Reimbursement execution is particularly important because payer implementation affects the timing and economics of future oncology growth.
Investment And Oncology Mix Pressure On MarginsThe company is spending aggressively on hiring, commercial expansion, and research while oncology mix may carry higher costs per test. If investment or oncology growth outpaces productivity and pricing benefits, margin expansion could pause or reverse over the next several quarters.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $150.44 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $4.62B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Nov 04, 2026 which is in 18 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on Aug 05, 2026. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.183 by -$0.033.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate is 0.15.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 42,644,386 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.15 in its last earnings report, missing expectations of $0.183. Following the earnings report the stock price went down -38.888%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$128.83 (29.62% Upside)
$128.83 (29.62% Upside)
Blogger Sentiment
Neutral
BLLN Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 19.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 7.3%
Last 30 Days ▼ 7.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
―
12-Months-Change
Fundamentals
Return on Equity
7.87%
Trailing 12-Months
Asset Growth
133.40%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a predominantly positive operational and financial picture: strong year-over-year revenue growth (64%), rapid test volume expansion (35%), material oncology growth (+176% YoY), sustained high gross margins (~70.5%), GAAP profitability, and a large cash balance ($549M). Management highlighted multiple product launches, supportive clinical data (NorthStar Response publication), low QC failure rates, and investments to scale commercial and lab capacity. Principal near-term headwinds are timing-related: reduced true-up revenue in the quarter, >$10M of claims held pending payer in‑network implementation, elevated operating expense from hiring and R&D, and potential short-term gross margin variability as oncology mix shifts. Given the strength of growth, profitability, product momentum and balance sheet versus the described timing and execution risks, the positives materially outweigh the negatives.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$128.83
▲(29.62% Upside)
Technical Analysis
Ownership Overview
7.47% Insiders
6.51% Mutual Funds
1.23% Other Institutional Investors
79.98% Public Companies and
Individual Investors